TY - JOUR T1 - Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2021-220077 SP - annrheumdis-2021-220077 AU - Sofia Ramiro AU - Rémy L M Mostard AU - Robert B M Landewé Y1 - 2021/02/16 UR - http://ard.bmj.com/content/early/2021/02/15/annrheumdis-2021-220077.abstract N2 - We read with interest the letter from De Santis et al1 on our COVID-19 High-intensity Immunosuppression in Cytokine storm syndrome (CHIC) study.2 We thank De Santis et al for sharing their word of caution on the widespread use of glucocorticoids that is indeed very relevant. We totally agree that (at least so far) it has only been demonstrated that patients with severe COVID-19 who need to be hospitalised benefit from treatment with systemic glucocorticoids, either in the form of methylprednisolone or dexamethasone.2 3 As emphasised by De Santis et al, no evidence has been … ER -